Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
Nafees Ahmad,Shama D. Ahuja,Onno W. Akkerman,Jan-Willem C. Alffenaar,Laura F Anderson,Parvaneh Baghaei,Didi Bang,Pennan M. Barry,Mayara Lisboa Bastos,Digamber Behera,Andrea Benedetti,Gregory P. Bisson,Martin J. Boeree,Maryline Bonnet,Sarah K. Brode,James C.M. Brust,Ying Cai,Eric Caumes,J. Peter Cegielski,Rosella Centis,Pei-Chun Chan,Edward D. Chan,Kwok-Chiu Chang,Macarthur Charles,Andra Cirule,Margareth Pretti Dalcolmo,Lia D'Ambrosio,Gerard de Vries,Keertan Dheda,Aliasgar Esmail,Jennifer Flood,Gregory J. Fox,Mathilde Fréchet-Jachym,Geisa Fregona,Regina Gayoso,Medea Gegia,Maria Tarcela Gler,Sue Gu,Lorenzo Guglielmetti,Timothy H. Holtz,Jennifer Hughes,Petros Isaakidis,Leah G. Jarlsberg,Russell R. Kempker,Salmaan Keshavjee,Faiz Ahmad Khan,Maia Kipiani,Serena P. Koenig,Won-Jung Koh,Afranio Lineu Kritski,Liga Kuksa,Charlotte Kvasnovsky,Nakwon Kwak,Zhiyi Lan,Christoph Lange,Rafael Laniado-Laborín,Myungsun Lee,Vaira Leimane,Chi-Chiu Leung,Eric Chung Ching Leung,Pei Zhi Li,Phil Lowenthal,Ethel Leonor Noia Maciel,Suzanne M. Marks,Sundari Mase,Lawrence Mbuagbaw,Giovanni Battista Migliori,Vladimir Milanov,Ann C. Miller,Carole D. Mitnick,Chawangwa Modongo,Erika Mohr,Ignacio Monedero,Payam Nahid,Norbert Ndjeka,Max R. O'Donnell,Nesri Padayatchi,Domingo Palmero,Jean W. Pape,Laura Jean Podewils,Ian R Reynolds,Vija Riekstina,Jérôme Robert,Maria I. Rodriguez,Barbara Seaworth,Kwonjune J. Seung,Kathryn Schnippel,Tae Sun Shim,Rupak Singla,Sarah Smith,Giovanni Sotgiu,Ganzaya Sukhbaatar,Payam Tabarsi,Simon Tiberi,Anete Trajman,Lisa Trieu,Zarir F Udwadia,Tjip S. van der Werf,Nicolas Veziris,Piret Viiklepp,Stalz Charles Vilbrun,Kathleen F. Walsh,Janice Westenhouse,Wing Wai Yew,Jae-Joon Yim,Nicola M. Zetola,Matteo Zignol,Dick Menzies +107 more
Reads0
Chats0
TLDR
Treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis, and the need for trials to ascertain the optimal combination and duration of these drugs is emphasised.About:
This article is published in The Lancet.The article was published on 2018-09-08 and is currently open access. It has received 404 citations till now. The article focuses on the topics: Bedaquiline & Absolute risk reduction.read more
Citations
More filters
Journal ArticleDOI
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Francesca Conradie,Andreas H. Diacon,Nosipho Ngubane,Pauline Howell,Daniel Everitt,Angela M. Crook,Mendel Carl M,Erica Egizi,Joanna Moreira,Juliano Timm,Timothy D. McHugh,G Wills,Anna Bateson,Robert D Hunt,Christo van Niekerk,Mengchun Li,Morounfolu Olugbosi,Melvin Spigelman +17 more
TL;DR: The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed.
Journal ArticleDOI
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Payam Nahid,Sundari Mase,Giovanni Battista Migliori,Giovanni Sotgiu,Graham H. Bothamley,Jan Brozek,Adithya Cattamanchi,J. Peter Cegielski,Lisa Chen,Charles L. Daley,Tracy Dalton,Raquel Duarte,Federica Fregonese,C. Robert Horsburgh,Faiz Ahmad Khan,Fayez Kheir,Zhiyi Lan,Alfred Lardizabal,Michael Lauzardo,Joan M. Mangan,Suzanne M. Marks,Lindsay McKenna,Dick Menzies,Carole D. Mitnick,Diana M. Nilsen,Farah Parvez,Charles A. Peloquin,Ann Raftery,H. Simon Schaaf,Neha Shah,Jeffrey R. Starke,John W. Wilson,Jonathan M. Wortham,Terence Chorba,Barbara Seaworth +34 more
TL;DR: New recommendations are made for the choice and number of drugs in a regimen, the duration of intensive and continuation phases, and the role of injectable drugs for MDR-TB.
Journal ArticleDOI
What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?
Surendra K Sharma,Keertan Dheda +1 more
TL;DR: National TB control programmes must have adequate laboratory infrastructure, trained healthcare workers and quality-assured laboratory DST reporting for both first-and second-line drugs to facilitate DSTguided treatment of DR-TB.
Journal ArticleDOI
Management of drug-resistant tuberculosis.
Christoph Lange,Keertan Dheda,Keertan Dheda,Keertan Dheda,Dumitru Chesov,Anna M. Mandalakas,Zarir F Udwadia,C. Robert Horsburgh +7 more
TL;DR: Individualised multidrug-resistant tuberculosis treatment with novel and repurposed drugs and guided by genotypic and phenotypic drug susceptibility testing can improve treatment outcomes.
Journal ArticleDOI
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
Fuad Mirzayev,Kerri Viney,Nguyen Nhat Linh,Licé González-Angulo,Medea Gegia,Ernesto Jaramillo,Matteo Zignol,Tereza Kasaeva +7 more
TL;DR: The 2020 revision of World Health Organization guidelines on the treatment of drug-resistant tuberculosis (TB) has highlighted the ongoing need for high-quality evidence and has reiterated the need for clinical trials and other research studies to contribute to the development of evidence-based policy.
References
More filters
Journal ArticleDOI
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
TL;DR: The propensity score is a balancing score: conditional on the propensity score, the distribution of observed baseline covariates will be similar between treated and untreated subjects, and different causal average treatment effects and their relationship with propensity score analyses are described.
Journal ArticleDOI
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Dennis Falzon,Ernesto Jaramillo,Holger J. Schünemann,Matthew Arentz,Melissa Bauer,Jaime Bayona,Léopold Blanc,Jose A. Caminero,Charles L. Daley,Chris Duncombe,Christopher Fitzpatrick,Agnes Gebhard,Haileyesus Getahun,Myriam Henkens,Timothy H. Holtz,J. Keravec,S. Keshavjee,Aamir J. Khan,R. Kulier,Vaira Leimane,Christian Lienhardt,Chunling Lu,Mar'iandyshev Ao,Giovanni Battista Migliori,Fuad Mirzayev,Carole D. Mitnick,Paul Nunn,G. Nwagboniwe,Olivia Oxlade,Domingo Palmero,Patricia B Pavlinac,M. I. D. Quelapio,Mario C. Raviglione,Michael Rich,S. Royce,Sabine Rüsch-Gerdes,A. Salakaia,R. Sarin,Delphine Sculier,Francis Varaine,Marco Vitoria,Judd L. Walson,Fraser Wares,Karin Weyer,Richard A. White,Matteo Zignol +45 more
TL;DR: The guidelines promote the early use of antiretroviral agents for TB patients with HIV on second-line drug regimens and systems that primarily employ ambulatory models of care are recommended over others based mainly on hospitalisation.
Journal ArticleDOI
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
Andreas H. Diacon,Alexander S. Pym,Martin P. Grobusch,R. F. Patientia,Roxana Rustomjee,Liesl Page-Shipp,Christoffel Pistorius,Rene Krause,Mampedi Bogoshi,Gavin J. Churchyard,Amour Venter,Jenny Allen,Juan Carlos Palomino,Tine De Marez,Rolf van Heeswijk,Nacer Lounis,Paul Meyvisch,Johan Verbeeck,Wim Parys,Karel de Beule,Koen Andries,David F Mc Neeley +21 more
TL;DR: The clinical activity of TMC207 validates ATP synthase as a viable target for the treatment of tuberculosis.
Journal ArticleDOI
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Andreas H. Diacon,Alexander S. Pym,Martin P. Grobusch,Jorge M. de los Rios,Eduardo Gotuzzo,Irina Vasilyeva,Vaira Leimane,Koen Andries,Nyasha Bakare,Tine De Marez,Myriam Haxaire-Theeuwes,Nacer Lounis,Paul Meyvisch,Els De Paepe,Rolf van Heeswijk,Brian Dannemann +15 more
TL;DR: The addition of bedaquiline to a preferred background regimen for 24 weeks resulted in faster culture conversion and significantly more culture conversions at 120 weeks, as compared with placebo.
Journal ArticleDOI
Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients
Shama D. Ahuja,David Ashkin,Monika Avendano,Rita Banerjee,Melissa Bauer,Jamie N. Bayona,Mercedes C. Becerra,Mercedes C. Becerra,Andrea Benedetti,Marcos Burgos,Rosella Centis,Eward D. Chan,Chen Yuan Chiang,Helen Cox,Lia D'Ambrosio,Kathy DeRiemer,Nguyen Huy Dung,Donald A. Enarson,Dennis Falzon,Katherine Flanagan,Jennifer Flood,Maria de Lourdes García-García,Neel R. Gandhi,Reuben Granich,Maria G. Hollm-Delgado,Timothy H. Holtz,Michael D. Iseman,Leah G. Jarlsberg,Salmaan Keshavjee,Hye-Ryoun Kim,Won-Jung Koh,Joey Lancaster,Christophe Lange,Wiel C M de Lange,Vaira Leimane,Chi Chiu Leung,Jiehui Li,Dick Menzies,Giovanni Battista Migliori,Sergey P. Mishustin,Carole D. Mitnick,Masa Narita,Philly O'Riordan,Madhukar Pai,Domingo Palmero,Seung-kyu Park,Geoffrey Pasvol,José María Peña,Carlos Pérez-Guzmán,M. I. D. Quelapio,Alfredo Ponce-de-León,Vija Riekstina,Jérôme Robert,Sarah Royce,H. Simon Schaaf,Kwonjune J. Seung,Lena Shah,Tae Sun Shim,Sonya Shin,Yuji Shiraishi,José Sifuentes-Osornio,Giovanni Sotgiu,Matthew Strand,Payam Tabarsi,Thelma E. Tupasi,Robert van Altena,Martie van der Walt,Tjip S. van der Werf,Mario H. Vargas,Pirett Viiklepp,Janice Westenhouse,Wing Wai Yew,Jae-Joon Yim +72 more
TL;DR: Findings from a collaborative, individual patient-level meta-analysis of treatment outcomes among patients with multidrug-resistant tuberculosis are reported.
Related Papers (5)
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Payam Nahid,Sundari Mase,Giovanni Battista Migliori,Giovanni Sotgiu,Graham H. Bothamley,Jan Brozek,Adithya Cattamanchi,J. Peter Cegielski,Lisa Chen,Charles L. Daley,Tracy Dalton,Raquel Duarte,Federica Fregonese,C. Robert Horsburgh,Faiz Ahmad Khan,Fayez Kheir,Zhiyi Lan,Alfred Lardizabal,Michael Lauzardo,Joan M. Mangan,Suzanne M. Marks,Lindsay McKenna,Dick Menzies,Carole D. Mitnick,Diana M. Nilsen,Farah Parvez,Charles A. Peloquin,Ann Raftery,H. Simon Schaaf,Neha Shah,Jeffrey R. Starke,John W. Wilson,Jonathan M. Wortham,Terence Chorba,Barbara Seaworth +34 more
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.
Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients
Shama D. Ahuja,David Ashkin,Monika Avendano,Rita Banerjee,Melissa Bauer,Jamie N. Bayona,Mercedes C. Becerra,Mercedes C. Becerra,Andrea Benedetti,Marcos Burgos,Rosella Centis,Eward D. Chan,Chen Yuan Chiang,Helen Cox,Lia D'Ambrosio,Kathy DeRiemer,Nguyen Huy Dung,Donald A. Enarson,Dennis Falzon,Katherine Flanagan,Jennifer Flood,Maria de Lourdes García-García,Neel R. Gandhi,Reuben Granich,Maria G. Hollm-Delgado,Timothy H. Holtz,Michael D. Iseman,Leah G. Jarlsberg,Salmaan Keshavjee,Hye-Ryoun Kim,Won-Jung Koh,Joey Lancaster,Christophe Lange,Wiel C M de Lange,Vaira Leimane,Chi Chiu Leung,Jiehui Li,Dick Menzies,Giovanni Battista Migliori,Sergey P. Mishustin,Carole D. Mitnick,Masa Narita,Philly O'Riordan,Madhukar Pai,Domingo Palmero,Seung-kyu Park,Geoffrey Pasvol,José María Peña,Carlos Pérez-Guzmán,M. I. D. Quelapio,Alfredo Ponce-de-León,Vija Riekstina,Jérôme Robert,Sarah Royce,H. Simon Schaaf,Kwonjune J. Seung,Lena Shah,Tae Sun Shim,Sonya Shin,Yuji Shiraishi,José Sifuentes-Osornio,Giovanni Sotgiu,Matthew Strand,Payam Tabarsi,Thelma E. Tupasi,Robert van Altena,Martie van der Walt,Tjip S. van der Werf,Mario H. Vargas,Pirett Viiklepp,Janice Westenhouse,Wing Wai Yew,Jae-Joon Yim +72 more